1	Impact of COVID-19 pandemic on the etiology and characteristics of
2	community-acquired pneumonia among children requiring
3	bronchoalveolar lavage in northern China
4	Rui-han Liu ^{1,2¶} , Yu-yan Zhang ^{1¶} , Zhou-hua Lu ¹ , Chang-qing Shen ¹ , Jin Wang ¹ ,
5	Qing Zhao ¹ , Tong-shu Hou ³ , Feng-hai Niu ¹ , Qing-xia Kong ^{1*} , Jun Ning ^{1*} , Lei
6	Yang ^{1,2*}
7	¹ Affiliated Hospital of Jining Medical University, Jining Medical University,
8	Jining, Shandong, China
9	² College of TCM, Shandong University of Traditional Chinese Medicine, Jinan,
10	Shandong, China
11	³ The Second Clinical Medical College, Binzhou Medical University, Yantai,
12	Shandong, China
13	¶These authors contributed equally to this work.
14	* co-corresponding authors
15	Corresponding authors
16	E-mail: kxdqy8@sohu.com(QXK)
17	E-mail: 18678766989@163.com(JN)
18	E-mail: yanglei8224982@163.com(LY)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 Abstract

20 Background:

To investigate the etiology and clinical characteristics of community-acquired pneumonia (CAP) among children requiring bronchoalveolar lavage (BAL) and analyze the impact of the coronavirus disease 2019 (COVID-19) pandemic on the pathogen spectrum and clinical manifestations.

25 Methods:

Children <14 years old hospitalized with CAP requiring BLA were enrolled between February 2019 to January 2020 and August 2021 to July 2022. Multiplex reverse transcription polymerase chain reaction (mRT-PCR) was used for pathogen detection. The demographic and clinical characteristics were compared between different pathogen-type infection groups, and before and during the COVID-19 pandemic.

32 **Results:**

Pathogen was detected in 91.66% (1363/1487) children. Mycoplasma 33 34 pneumoniae, adenovirus and human rhinovirus were the most frequently detected pathogens. The frequency of detection of virus infections and 35 co-infections was decreased during the pandemic, but the detection of atypical 36 bacterial infections was increased. The clinical manifestations and the results 37 of CT scans and fiberoptic bronchoscopy showed a significant difference 38 between different types of pathogen infection, and lung inflammation was 39 reduced during the COVID-19 pandemic compared with before the pandemic. 40

41 **Conclusions:**

42	M. pneumoniae infection might be the greatest pediatric disease burden
43	leading to CAP in northern China. Wearing masks and social distancing in
44	public places during the COVID-19 pandemic effectively reduced the
45	transmission of respiratory viruses, but it did not reduce the infection rate of <i>M</i> .
46	pneumoniae. In addition, these interventions significantly reduced lung
47	inflammation in children compared with before the pandemic.

48 Introduction

Community-acquired pneumonia (CAP) is a common infection that presents a 49 50 serious public health threat among children under 5 years of age. CAP was responsible for 13.9% of childhood deaths among the under-5s worldwide in 51 2019[1]. Although this was more than 1,001,000 fewer deaths compared with 52 the year 2000, the number of complicated and severe pneumonia cases has 53 increased considerably over the past two decades[2,3]. Following the 54 introduction of the pneumococcal conjugate vaccine and the Haemophilus 55 56 influenzae type b vaccine, respiratory viruses and atypical bacteria have become the most frequent etiologic agents in recent years[4]. 57

The outbreak of coronavirus disease 2019 (COVID-19) constitutes a 58 59 substantial health burden across the globe. To control the COVID-19 pandemic, governments around the world implemented a series of 60 non-pharmaceutical interventions (NPIs), such as mandated facial masks, 61 encouraged social distancing, remote working, online teaching, stay-at-home 62 orders and travel restrictions. Studies have shown that the preventive 63 measures useful in containing COVID-19 also seemed to be effective in 64 preventing the transmission of other respiratory viruses[5-11]. Considering the 65 impact of etiology on disease severity, mortality and long-term sequelae in 66 children with CAP[12], it is necessary to identify the causative pathogen. 67

68 Nasopharyngeal swabs or aspirate specimens are usually used for 69 pathogen detection in children with CAP. However, the detection of

70 microorganisms from the upper respiratory tract may not directly correlate with the pathogenic agents of pneumonia[13]. Over the past two decades, 71 72 fiberoptic bronchoscopy (FB) and bronchoalveolar lavage (BAL) have become important diagnostic and therapeutic procedures for severe pneumonia. 73 74 Bronchoalveolar lavage fluid (BALF) collected directly from the foci of inflammation can be used as reliable samples for pathogen identification[14]. 75 Furthermore, advances in molecular detection technology have contributed to 76 rapid and accurate pathogen identification. Automated capillary 77 the 78 electrophoresis combined with multiplex reverse transcription polymerase chain reaction (mRT-PCR) has been developed to detect microorganisms, at 79 reasonable cost and acceptable levels of sensitivity and specificity[15]. 80

In this study, we report and discuss the impact of the COVID-19 pandemic on the spectrum of common respiratory pathogens among children with CAP requiring FB plus BAL in northern China. Additionally, changes in the pathogen spectrum and the clinical manifestations in the children were analyzed systematically and compared prior to the COVID-19 pandemic (February 2019 to January 2020) and during the COVID-19 pandemic (August 2021 to July 2022).

88 Materials and methods

89 Ethics approval

This study was approved by the Ethics Committee of the Affiliated Hospital of
Jining Medical University (No.: 2020C076).

92 Study population

Between February 2019 to January 2020 and August 2021 to July 2022, a total 93 94 of 1487 children under the age of 14 who required BAL were included in our study. It was ensured by experienced physicians that the following inclusion 95 96 criteria were met. (1) All of the children were in the acute stage of pneumonia. (2) Symptoms persisted for at least 7 days after the initiation of treatment 97 and/or the patient was not responding to treatment, or breathing was labored. 98 or the child became distressed or agitated, or their oxygen saturation level was 99 100 < 92%. (3) Auscultation revealed decreased/absent breath sounds, or tubular breath sounds, and or a repeated fixed wheeze. (4) Radiographic inspection 101 revealed pulmonary atelectasis, or pulmonary emphysema, or mediastinal 102 103 emphysema, or pulmonary consolidation. Exclusion criteria were as follows: children with immunodeficiency disease, congenital heart 104 disease, tracheostomy tube, cystic fibrosis, hemopoietic system malignant tumor, 105 106 recent hematopoietic stem-cell or solid-organ transplant, children with an alternative respiratory disorder diagnosis or newborns less than 1 month old. 107 Written informed consent was obtained from parents/guardians before children 108 underwent FB plus BAL. 109

110 Sample and data collection

For the purpose of treatment, FB combined with BAL was performed by experienced bronchoscopists according to the recommendation of the European Respiratory Society Task Force[16]. Approximately 3 mL of BALF

was collected from each patient and the samples were aliquoted and stored at
-80°C within 2 hours simultaneously. Diagnosis of the morphology under
bronchoscopy was made by two experienced physicians[17,18].

The presence of pulmonary consolidation, infiltration, pleural effusion and pericardial effusion in the CT scans was considered evidence of pneumonia[19]. The CT scans were reviewed by three senior radiologists independently to ensure the accuracy and consistency of the diagnosis. The other clinical data were extracted from electronic medical records after the patient was discharged.

123 Pathogen detection

The SureX 13 respiratory pathogen multiplex kit (Ningbo Health Gene Technologies Ltd.) was used to simultaneously detect common virus and atypical bacteria in 200 µL of BALF. The mRT-PCR products were analyzed on the Applied Biosystems 3500Dx Genetic Analyzer with LIZ500 as the internal standard, and then analyzed with GeneMapper 4.1 software (Thermo Fisher Scientific, Waltham, MA, USA).

A viral or atypical bacterial pathogen was considered to be present if influenza A virus (Flu A, including 2009 H1N1 pandemic and H3N2), influenza B virus (Flu B), parainfluenza virus (PIV), adenovirus (AdV), respiratory syncytial virus (RSV), human rhinovirus (HRV), human metapneumovirus (hMPV), human bocavirus (HBoV), coronavirus (CoV), *Mycoplasma pneumoniae* or *Chlamydophila pneumoniae* was detected in the BALF.

Co-infection was considered when two or more viral or atypical bacterialpathogens were detected in one child.

138 Statistical analysis

Considering the similar clinical features observed between children with virus–virus co-infections and single virus infections, these cases were combined into the virus group in the tables. This also applied to those with one or two atypical bacterial infections, who were combined in the atypical bacterium group. The clinical characteristics of enrolled children were stratified and described according to the following groups: virus or atypical bacterium only infection, and co-infection (virus–atypical bacterium infections).

All statistical analyses were performed using SAS software, version 9.4 146 147 (SAS Institute Inc., NC, USA). The median and guartile [M (P25, P75)] values were used to describe quantitative data with a non-normal distribution, and the 148 frequency (component ratio) [n (%)] was used to describe classified data. The 149 150 Chi-squared test was used to analyze differences in sex, age, the season of disease onset and the infecting pathogens between samples collected before 151 and during the COVID-19 pandemic. The Kruskal-Wallis H test was used to 152 compare the time from illness onset to admission, the duration of 153 hospitalization, and the presence of a fever and cough in different groups 154 between different time periods. Fisher's exact test was used to compare the 155 difference in the proportion of different pathogens between samples taken 156 before and during the COVID-19 pandemic. Trends in the infection rates of 157

various pathogens in different age groups were assessed 158 bv the Cochran-Armitage trend test. The differences in clinical manifestations, CT 159 160 scans and FB results between the various groups and different time periods were also analyzed by Fisher's exact test. A probability (p) value less than 0.05 161 was considered statistically significant. For pairwise comparison of multiple 162 groups of samples, Bonferroni correction was used to inspect the standard of 163 each comparison, $\alpha' = 0.01667 (0.05/3)$. 164

165 **Results**

166 **Demographic characteristics**

From February 2019 to January 2020 and August 2021 to July 2022, 696 and 167 791 children were enrolled in this study, respectively (Table 1). A total of 168 169 54.74% of the children were boys, and the median age was 70.51±32.79 months. The median time from illness onset to admission and the median 170 duration of hospitalization were 8 (6,10) days and 7 (6,9) days, respectively. 171 The proportion of children undergoing FB combined with BAL gradually 172 increased with age (X²/Z=54.0288, P<0.001), and the proportion of children 173 affected during autumn was significantly higher than that in the other seasons. 174 Compared with before the COVID-19 pandemic, the median time from 175 illness onset to hospitalization was reduced [8 (6,11) days vs 7 (6,10) days; 176 P=0.0031] and the median hospitalization time was also reduced [8 (7,9) days 177 vs 7 (6,8) days; P<0.001] in the children enrolled during the COVID-19 178 pandemic. During the COVID-19 pandemic, the pathogen detection rate 179

Variables	Total	Before	Ongoing	X ² / Z	Р
Number	1487	696	791	-	_
Sex (male), No. (%) ^a	814(54.74)	385(55.32)	429(54.24)	0.1746	0.676
Time from illness onset to admission (days), mean(P25, P75) ^b	8(6,10)	8(6,11)	7(6,10)	8.748	0.0031
Duration of hospitalization (days), mean(P25, P75) ^b	7(6,9)	8(7,9)	7(6,8)	48.1227	<0.001
Age (mo), mean ± SD ª	70.51±32.79	64.41±32.43	75.87±32.19		
age < 3 yrs, No. (%)	229(15.40)	149(21.41)	80(10.11)		
3 yrs. ≤ age < 5 yrs, No. (%)	357(24.01)	170(24.43)	187(23.64)	54.0000	<0.001
5 yrs. ≤ age < 7 yrs, No. (%)	427(28.72)	207(29.74)	220(27.81)	54.0288	
7 yrs. ≤ age < 14 yrs, No. (%)	474(31.88)	170(24.43)	304(38.43)		
Incident season, No. (%) ^a		,			
Spring (Mar, Apr, May)	170 (11.43)	116(16.67)	54(6.83)		
Summer (Jun, Jul, Aug)	237 (15.94)	89(12.79)	148(18.71)	40.0070	
Fall (Sep, Oct, Nov)	640(43.04)	291(41.81)	349(44.12)	40.2873	<0.00
Winter (Dec, Jan, Feb)	440(29.59)	200(28.74)	240(30.34)		

180 Table 1 Demographic characteristics of children with community-acquired pneumonia requiring Flexible bronchoscopy and bronchoalveolar lavage

181 Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the total

182 number.

183 **a.** Chi-square test was used to analyze the differences in gender, age and onset seasons between before COVID-19 pandemic and during COVID-19

- 184 pandemic.
- 185 b. Kruskal-Wallis H Test was used to compare the time from illness onset to admission and duration of hospitalization in different groups between different
- 186 period.

decreased from 20% to ~10% in children under 3 years of age and increased from 25% up to ~40% in children aged over 7 years. There was also a statistical difference in the season of illness onset among the children $(X^2/Z=40.2873, P<0.001)$, with a lower incidence of disease in spring (16.67% vs 6.83%) and a higher incidence in summer (12.79% vs 18.71%) during the COVID-19 pandemic (Table 1).

193 Pathogen spectrum

Among the enrolled children, ≥ 1 pathogen was detected in 91.66% (1363/1487) 194 195 of children and the pathogen detection rate gradually increasing with age (Z=-6.425, P<0.001). The specific pathogens detected are listed in Table 2, 196 sorted by descending detection rates. AdV (n=64, 4.30%), HRV (n=41, 2.76%), 197 198 PIV (n=21, 1.41%) and Flu B (n=21, 1.41%) were the most common viral pathogens among the enrolled cases. There were statistically significant 199 differences in the age of children infected with viruses, with the number of 200 201 children infected with viruses decreasing with increased age, except for Flu B (P=0.1927) and hMPV (P=0.1447). Children younger than 3 years were more 202 vulnerable to AdV, PIV and RSV infection, whereas children older than 3 years 203 were more susceptible to atypical bacterial infection. A total of 1254 (84.33%) 204 cases were found to be infected with M. pneumoniae, and the number of 205 children with *M. pneumoniae* infection increased with age (Z=-10.2742, 206 P<0.001). 207

208 Compared with before the COVID-19 pandemic, the number of children

	-			•	-		
Pathogen Detected	Total No. (%)	< 3 years No. (%)	3–5 years No. (%)	5–7 years No. (%)	7–14 years No. (%)	Z	р
Participants, n	1487	229	357	427	474	-	-
≥1 pathogen detected	1363(91.66)	186(81.22)	319(89.36)	407(95.32)	451(95.15)	-6.425	<0.001
Virus			•			·	
AdV ^a	64(4.30)	19(8.30)	25(7.00)	13(3.04)	7(1.48)	4.9844	<0.001
HRV ^a	41(2.76)	10(4.37)	11(3.08)	11(2.58)	9(1.90)	1.8833	0.0298
PIV ^a	21(1.41)	12(5.24)	5(1.40)	2(0.47)	2(0.42)	4.6023	<0.001
Flu B	21(1.41)	5(2.18)	2(0.56)	11(2.58)	3(0.63)	0.8681	0.1927
RSV ^a	19(1.28)	11(4.80)	2(0.56)	4(0.94)	2(0.42)	3.8454	<0.001
Flu A ^a	10(0.67)	6(2.62)	2(0.56)	0(0.00)	2(0.42)	2.9073	0.0018
HBoV ^a	8(0.54)	5(2.18)	1(0.28)	1(0.23)	1(0.21)	2.7325	0.0031
hMPV	8(0.54)	2(0.87)	2(0.56)	3(0.7)	1(0.21)	1.0593	0.1447
CoV ^a	2(0.13)	1(0.44)	1(0.28)	0(0.00)	0(0.00)	1.6974	0.0448
Atypical bacteria							
M.pneumonia ª	1254(84.33)	142(62.01)	291(81.51)	381(89.23)	440(92.83)	-10.2742	<0.001
C.pneumoniae	4(0.27)	1(0.44)	0(0.00)	1(0.23)	2(0.42)	-0.4335	0.3323

Table 2 Prevalence of causative respiratory pathogen according to age groups in children performed with FOB combined with BAL

210 Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the total

211 number.

 $^{a}p < 0.05$, Cochran-Armitage Trend Test was used to compare trends of infection rates of various pathogens in different age groups.

Pathogen Detected	Total, No. (%)	Before, No. (%)	Ongoing, No. (%)			
Participants, n	1487	696	791	X ² /Z	р	
Virus	107(7.20)	69(9.91)	38(4.80)			
Atypical bacteria	1177(79.15)	515(73.99)	662(83.69)	20 1146	10.004	
Co-infection	79(5.31)	51(7.33)	28(3.54)	28.1146	<0.001	
No pathogenic detected	124(8.34)	61(8.76)	63(7.96)			
Virus				A A)	
AdV ^a	64(4.30)	40(5.75)	24(3.03)	0.0	105	
HRV ª	41(2.76)	29(4.17)	12(1.52)	0.0022		
PIV	21(1.41)	13(1.87)	8(1.01)	0.1894		
Flu B ª	21(1.41)	15(2.16)	6(0.76)	0.0	271	
RSV	19(1.28)	8(1.15)	11(1.39)	0.8182		
Flu A ^a	10(0.67)	10(1.44)	0(0.00)	0.0	005	
HBoV ^a	8(0.54)	7(1.01)	1(0.13)	0.0293		
hMPV	8(0.54)	3(0.43)	5(0.63)	0.73	303	
CoV	2(0.13)	2(0.29)	0(0.00)	0.2189		
Atypical bacteria				F)	
M.pneumonia ª	1254(84.33)	564(81.03)	690(87.23)	0.0	0.0013	
C.pneumoniae ª	4(0.27)	4(0.57)	0(0.00)	0.0	478	

Table 3 Distribution of various pathogens in children patients performed with FOB combined with BAL

214 Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the number.

 $^{a}p < 0.05$, Fisher's Exact Test was used to compare the differences between alone and co-infection of each pathogen in different period.

216	infected with AdV (5.75% vs 3.03%, P=0.0105), HRV (4.17% vs 1.52%,
217	P=0.0022), Flu B (2.16% vs 0.76%, P=0.0271), Flu A (1.44% vs 0.00%,
218	P=0.0005) and HBoV (1.01% vs 0.13%, P=0.0293) decreased significantly.
219	Therefore, the total proportion of cases of viral infection (9.91% vs 4.80%) and
220	co-infection (7.33% vs 3.54%) decreased significantly. Whereas the proportion
221	of cases of <i>M. pneumoniae</i> infection had a further increasing that compared
222	with before the pandemic (87.23% vs 81.03%, P=0.0013) (Table 3).

Clinical characteristics between three infection groups 223

224 Children with viral infection showed the shortest duration of fever [4 (0,6) days], while those with atypical bacterial infection [7 (5,9) days vs 4 (0,6) days, 225 P<0.001] or co-infection [7 (4,10) days vs 4 (0,6) days, P=0.0002] showed 226 227 longer duration of fever, and the differences among the three groups were statistically significant (P<0.001). The incidence of wheezing in children 228 infected with virus (18.69% vs 3.91%, P<0.001) and those with co-infection 229 230 (15.19% vs 3.91%, P=0.0001) was significantly higher than in those with atypical bacterial infection (3.91%). Compared with the atypical bacterial 231 infection group, viral infection made children more prone to dyspnea (8.41% vs 232 1.44%, P=0.0001), diarrhea (15.89% vs 6.73%, P=0.0019), rhonchi (47.66% 233 vs 28.63%, P=0.0003) and chest indrawing (9.35% vs 1.7%, P=0.0001). 234 Decreased breath sounds (59.64%) and rales (66.10%) were the most 235 common signs in the atypical bacterial infection group. No remarkable 236 differences in the duration of cough, fatigue, lack of appetite, abdominal pain, 237

Table 4 Comparison of clinical and laboratory findings according to respiratory pathogens in children performed with FOB combined with BAL

Characteristic	Total N=1363	Virus ¹ N=107	Atypical Bacteria ² N=1177	Co-infection ³ N=79	P value	P value ° (1-2)	P value ° (1-3)	P value ^c (2-3)
Clinical data								
Duration of fever,mean(P25, P75) a	7(5,8)	4(0,6)	7(5,9)	7(4,10)	<0.001	<0.001	0.0002	0.7161
Duration of cough,mean(P25, P75) a	7(5,9)	6(4,13)	7(5,9)	8(5,11)	0.3451	0.5847	0.8112	0.1543
Fatigue ^b	17(1.25)	3(2.80)	12(1.02)	2(2.53)	0.1035	0.1228	1	0.2184
Dyspnea ^b	29(2.13)	9(8.41)	17(1.44)	3(3.80)	0.0001	0.0001	0.2422	0.1262
Wheezing ^b	78(5.72)	20(18.69)	46(3.91)	12(15.19)	<0.001	<0.001	0.5621	0.0001
Lack of appetite ^b	830(60.9)	66(61.68)	719(61.09)	45(56.96)	0.7557	1	0.5476	0.4769
Abdominal pain ^b	227(16.65)	15(14.02)	201(17.08)	11(13.92)	0.6354	0.5000	1	0.5375
Diarrhea ^b	100(7.34)	17(15.89)	75(6.37)	8(10.13)	0.0019	0.0012	0.2845	0.2356
Chest pain ^b	40(2.93)	4(3.74)	33(2.80)	3(3.80)	0.5852	0.5424	1	0.4907
Physical sign								
Decreased breath sounds ^b	770(56.49)	35(32.71)	702(59.64)	33(41.77)	<0.001	<0.001	0.2208	0.0021
Rales ^b	887(65.08)	60(56.07)	778(66.10)	49(62.03)	0.0957	0.0436	0.4535	0.4640
Rhonchi ^b	415(30.45)	51(47.66)	337(28.63)	27(34.18)	0.0003	<0.001	0.0727	0.3062

Tachypnea ^b	47(3.45)	5(4.67)	39(3.31)	3(3.80)	0.571	0.4065	1	0.744
Chest indrawing ^b	33(2.42)	10(9.35)	20(1.70)	3(3.80)	0.0001	<0.001	0.2437	0.1718
CT scan								
Consolidation ^b	1034(75.86)	60(56.07)	926(78.67)	48(60.76)	<0.001	<0.001	0.5505	0.0007
Single lobar infiltrate ^b	519(38.08)	30(28.04)	465(39.51)	24(30.38)	0.0222	0.0222	0.7462	0.1215
Multilobar infiltrates (unilateral) ^b	377(27.66)	19(17.76)	333(28.29)	25(31.65)	0.0408	0.0177	0.0359	0.5214
Multilobar infiltrates (bilateral) ^b	436(31.99)	50(46.73)	358(30.42)	28(35.44)	0.0024	0.0007	0.135	0.3781
Pleural effusion ^b	236(17.31)	13(12.15)	211(17.93)	12(15.19)	0.2979	0.1445	0.6644	0.6486
Pericardial effusion ^b	37(2.71)	4(3.74)	29(2.46)	4(5.06)	0.2135	0.3478	0.7244	0.1485
Fiberoptic bronchoscopy						1	1	
Mucosal hyperemia and/or edema b	820(60.16)	69(64.49)	714(60.66)	37(46.84)	0.0348	0.4699	0.0174	0.0176
Mucosal erosion and/or necrosis b	543(39.84)	38(35.51)	463(39.34)	42(53.16)	0.0348	0.4699	0.0174	0.0176
Bronchial mucus plugs ^b	224(16.43)	2(1.87)	214(18.18)	8(10.13)	<0.001	<0.001	0.0193	0.0919
Plastic bronchitis ^b	171(12.55)	2(1.87)	162(13.76)	7(8.86)	0.0002	<0.001	0.0382	0.3048
Bronchial atresia ^b	23(1.69)	6(5.61)	14(1.19)	3(3.80)	0.0023	0.0043	0.7352	0.0861
Bronchiectasis ^b	11(0.81)	5(4.67)	5(0.42)	1(1.27)	0.0006	0.0007	0.2433	0.3233

239 Group 1, Virus alone infection; group 2, Atypical Bacteria alone infection; group 3, Virus-Atypical bacteria co-infection.

- a. Kruskal-Wallis H tests were conducted to compare groups.
- 241 b. Fisher exact tests were conducted to compare groups.
- 242 C. Bonferroni correction was conducted to pairwise comparison of multiple groups of samples.

chest pain and tachypnea were observed between the three groups (Table 4). 243 In CT scan findings, both consolidation and infiltration revealed prominent 244 differences among the different infection groups. Atypical bacterial infection 245 was most likely to cause consolidation (P<0.001) and single lobar infiltration 246 (P=0.0222). Compared with the atypical bacterial infection group, the virus 247 infection group was more likely to lead to bilateral multilobar infiltration 248 (46.73% vs 30.42%, P=0.0007), whereas unilateral multilobar infiltration was 249 more common in the atypical bacterial infection group than in the virus 250 251 infection group (28.29% vs 17.76%, P=0.0177) or the co-infection group (31.65% vs 17.76%, P=0.0359) (Table 4). 252

The FB findings showed that compared with the viral infection and atypical 253 254 bacterial infection groups, the co-infection group presented more severe tracheal mucosal injury. The proportion of more severe mucosal erosion 255 and/or necrosis was the highest in co-infection group (53.16% vs 35.51%, 256 P=0.0174; 53.16% vs 39.34%, P=0.0176). Compared with the viral infection 257 group, bronchial mucus plugs and plastic bronchitis were more frequently 258 detected in children with atypical bacterial infections (18.18% vs 1.87%, 259 P<0.001) and co-infections (10.13% vs 1.87%, P=0.0193). Compared with the 260 atypical bacterial infection group, virus infection was more likely to give rise to 261 alterations in bronchial lumen morphology, which included bronchial atresia 262 (5.61% vs 1.19%, P=0.0043) and bronchiectasis (4.67% vs 0.42%, P=0.0007) 263 (Table 4). 264

Clinical characteristics before and during the COVID-19 pandemic

Compared with before the COVID-19 pandemic, clinical symptoms and 266 pulmonary signs in the enrolled children during the pandemic showed a shorter 267 duration of cough [7 (5,10) days vs 6 (4,9) days; P<0.001], a decreased 268 proportion of rhonchi dyspnea (38.11% vs 23.76%, P<0.001) and chest 269 indrawing (3.46% vs 1.51%, P=0.0216), but an increased proportion of chest 270 pain (1.89% vs 3.85%, P=0.0364), decreased breath sounds (47.87% vs 271 64.01%, P<0.001) and rales (49.92% vs 78.30%, P<0.001). CT scans 272 273 revealed that the proportions of consolidation (91.76% vs 57.64%, P<0.001) and unilateral multilobar infiltrates (32.55% vs 22.05%, P<0.001) were higher 274 than before the COVID-19 pandemic, but the proportions of bilateral multilobar 275 276 infiltrates (28.57% vs 35.91%, P=0.0043) and pleural effusion (13.74% vs 21.42%, P=0.0002) were lower than before the COVID-19 pandemic. The FB 277 findings revealed an increased proportion of mucosal hyperemia and/or edema 278 (27.09% vs 89.01%, P<0.001), which corresponded to the decreased 279 proportion of mucosal erosion and/or necrosis (72.91% vs 10.99%, P<0.001). 280 Despite a significant increase in the proportion of bronchial mucus plugs 281 (13.70% vs 18.82%, P=0.0126), there was a significant reduction in bronchial 282 atresia (3.31% vs 0.27%, P<0.001) and bronchiectasis (1.57% vs 0.14%, 283 P=0.0039). The above results suggest that lung inflammation in the enrolled 284 children was significantly alleviated compared with before the COVID-19 285 pandemic (Table 5). 286

Characteristic	Total n=1363	Before n=635	Ongoing n=728	P value
Clinical data			1	_
Duration of fever, mean (P25, P75) ^a	7(5,8)	7(5,9)	7(5,8)	0.4202
Duration of cough,mean(P25, P75) ^a	7(5,9)	7(5,10)	6(4,9)	<0.001
Fatigue ^b	17(1.25)	10(1.57)	7(0.96)	0.337
Dyspnea ^b	29(2.13)	19(2.99)	10(1.37)	0.0581
Wheezing ^b	78(5.72)	41(6.46)	37(5.08)	0.2941
Lack of appetite ^b	830(60.9)	379(59.69)	451(61.95)	0.4043
Abdominal pain ^b	227(16.65)	98(15.43)	129(17.72)	0.2747
Diarrhea ^b	100(7.34)	50(7.87)	50(6.87)	0.5323
Chest pain ^b	40(2.93)	12(1.89)	28(3.85)	0.0364
hysical sign				
Decreased breath sounds ^b	770(56.49)	304(47.87)	466(64.01)	<0.001
Rales ^b	887(65.08)	317(49.92)	570(78.30)	<0.001
Rhonchi ^b	415(30.45)	242(38.11)	173(23.76)	<0.001

Table5 Comparison of clinical and laboratory findings before and during COVID-19 pandemic in children performed with FOB combined with BAL

	-				
	Tachypnea ^b	47(3.45)	19(2.99)	28(3.85)	0.4576
	Chest indrawing ^b	33(2.42)	22(3.46)	11(1.51)	0.0216
C	CT scan				
	Consolidation ^b	1034(75.86)	366(57.64)	668(91.76)	<0.001
	Single lobar infiltrate ^b	519(38.08)	245(38.58)	274(37.64)	0.7374
	Multilobar infiltrates (unilateral) ^b	377(27.66)	140(22.05)	237(32.55)	<0.001
	Multilobar infiltrates (bilateral) ^b	436(31.99)	228(35.91)	208(28.57)	0.0043
	Pleural effusion ^b	236(17.31)	136(21.42)	100(13.74)	0.0002
	Pericardial effusion ^b	37(2.71)	15(2.36)	22(3.02)	0.5065
F	iberoptic bronchoscopy				
	Mucosal hyperemia and/or edema b	820(60.16)	172(27.09)	648(89.01)	<0.001
	Mucosal erosion and/or necrosis b	543(39.84)	463(72.91)	80(10.99)	<0.001
	Bronchial mucus plugs ^b	224(16.43)	87(13.70)	137(18.82)	0.0126
	Plastic bronchitis ^b	171(12.55)	86(13.54)	85(11.68)	0.3255
	Bronchial atresia ^b	23(1.69)	21(3.31)	2(0.27)	<0.001
	Bronchiectasis ^b	11(0.81)	10(1.57)	1(0.14)	0.0039

288 Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the number.

- 289 a. Kruskal-Wallis H tests were conducted to compare groups.
- b. Fisher exact tests were conducted to compare groups.

291 Discussion

Respiratory pathogen detection in nasopharyngeal swabs, oropharyngeal 292 293 swabs and even endotracheal aspirates may not fully represent the etiology of pneumonia[20]. Thus, most children with CAP may not receive treatment 294 based on a reliable etiological diagnosis. Furthermore, the pathogen spectrum 295 of respiratory tract infections is affected by age, geography, and environmental, 296 social, economic and other factors. It is therefore necessary to definitively 297 address the spectrum of respiratory pathogens involved in pediatric CAP. The 298 299 aim of this study was to evaluate the etiologies in children with CAP requiring BAL. In addition, the influence of the COVID-19 pandemic on the pathogens 300 and the clinical manifestations in the children were analyzed. 301

302 We found that the positive rate of pathogen detection was 91.66%. The high etiological detection rate may be mainly attributable to our use of mRT-PCR on 303 specimen from the foci of inflammation. The most common pathogen was M. 304 305 pneumoniae, which was detected in more than four-fifths of all cases, with a remarkable over-representation among children older than 3 years of age. This 306 proportion was higher than that reported in other studies (Lee et al. 45.3% in 307 South Korea[4] and Gao et al. 37.5% in north China[3]. Considering that 308 309 patients who required BAL in addition to intravenous medical treatment had more severe pneumonia, this difference may partly be explained by the 310 311 differences in the studied populations.

Virus was detected in 12.51% (186/1487) of our enrolled cases. Unlike our

results, one or more viruses were detected in 73% of children hospitalized for 313 CAP in the United States[21]. Furthermore, a higher percentage of children 314 315 (94.3%) were reported with severe acute respiratory infection in China during the 2009 H1N1 pandemic and post-pandemic period[22]. With the differences 316 317 in study sites, populations, as well as study years and duration, the proportions varied largely between studies. Of the 186 children infected with virus, AdV 318 was the most prevalent in the present study representing 34.41% (64/186) of 319 cases, which was in line with a study in Cameroon among children with severe 320 321 acute respiratory infections[23]. However, the majority of similar studies reported RSV as the most commonly detected viral pathogen[20,21]. In the 322 present study, RSV ranked fifth with a relatively low positive detection rate of 323 324 10.22% (19/186). Co-infections were observed in nearly half of the patients (42.47%, 79/186) that tested positive for virus infection. This suggests that 325 severe viral-related CAP is often accompanied by atypical bacterial infection. 326

327 The COVID-19 pandemic and the NPIs undertaken during the pandemic significantly affected the transmission of common respiratory pathogens. 328 Compared with before the COVID-19 pandemic, the overall detection rate of 329 viral pathogens was lower during the COVID-19 pandemic. However, the 330 331 detection rate of atypical bacterial pathogens increased. The decreased detection of AdV, HRV, Flu B, Flu A and HBoV greatly contributed to the 332 overall reduction in viral pathogens. In accordance with our results, a 333 significant decrease in the detection of AdV, Flu B and Flu A was also 334

observed in children with a lower respiratory tract infection during the 335 COVID-19 pandemic in southern China[5] and a considerable reduction in all 336 viral respiratory infections was observed in a large Italian tertiary hospital[6]. In 337 a study conducted in southern China, the detection rates of *M. pneumoniae* 338 339 using nasopharyngeal swabs of inpatients with acute respiratory infection were also unprecedentedly reduced from 20% in 2019 to 1.0% in 2020[7]. However, 340 another study using BALF from a city in northern China, showed that M. 341 pneumoniae was the most frequently detected pathogen, at a rate of up to 342 343 73.55%[24]. Furthermore, the detection of *M. pneumoniae* further increased despite the NPIs that were adopted during the COVID-19 pandemic. The main 344 reason for this phenomenon might be the long-term colonization of M. 345 346 pneumoniae in the upper respiratory tract[25].

In aspect to clinical manifestations, we found that children with atypical 347 bacterial infections more frequently displayed a longer duration of fever, and a 348 349 higher proportion of decreased breath sounds and rales. However, dyspnea, wheezing, diarrhea, rhonchi and chest indrawing were more frequent among 350 children with a viral infection. Similar to other studies[26], compared with 351 children with viral pneumonia, *M. pneumoniae*-positive children were 352 significantly more likely to report a long duration of symptoms before 353 hospitalization, and decreased breath sounds and rales, but were less likely to 354 report dyspnea, wheezing, diarrhea, rhonchi and chest indrawing. Such 355 findings may help inform clinicians of the preliminary differentiation between 356

357 viral and atypical bacterial infections.

On CT scans, consolidation and unilateral lung infiltration were often seen in 358 359 the atypical bacterial infection group, whereas bilateral lung infiltration was more common in the viral infection group, suggesting that pulmonary 360 361 inflammation caused by *M. pneumoniae* is relatively limited to unilateral lung tissue, while viral infection affected bilateral lung tissues in nearly half of the 362 children. This finding was consistent with another study that compared the 363 radiographic findings of children hospitalized for CAP with and without M. 364 365 pneumoniae using data from the EPIC study[27]. FB results indicated more serious inflammatory changes in the mucosa, increasing the likelihood of this 366 condition developing into bronchial mucus plugs and even bronchial dendritic 367 368 casts in *M. pneumoniae*-infected children. The presence of bronchial mucus plugs, as detected by FB, is independently associated with a longer time 369 period to radiographic clearance in patients with refractory *M. pneumoniae* 370 371 pneumonia[28]. Wang et al. reported that in 86.6% of children with plastic bronchitis the causative agent was M. pneumoniae[29] and this result was 372 consistent with our findings. Bronchial atresia and/or bronchiectasis of the 373 distal airway mostly occurred in children infected with virus. Despite few 374 articles related to bronchial lumen morphological changes during the acute 375 stage of pneumonia, our experienced bronchoscopists found that bronchial 376 lumen dilation can be reversed with appropriate treatment. It was unfortunate 377 that bronchial atresia was usually not reversible. Thus, the results highlighted 378

the necessity for careful management and long-term follow-up of patients with
mucus plugs, plastic bronchitis and bronchial lumen morphological changes.

381 Several studies have reported the impact of the COVID-19 pandemic on the pathogen spectrum of respiratory tract infections in children[5-7,24], but the 382 corresponding differences in clinical manifestations have rarely been studied. 383 During the COVID-19 pandemic, we found a decreased proportion of rhonchi, 384 chest indrawing, bilateral lung infiltrates and bronchial lumen morphological 385 changes, but a significantly higher proportion of decreased breath sounds, 386 387 rales, consolidation, unilateral lung infiltrates and bronchial mucus plugs. Considering that the clinical manifestations of the children were consistent with 388 a higher detection rate of *M. pneumoniae*, a possible explanation for this 389 390 difference was a decrease in viral infection accompanied by an increase in M. pneumoniae infection. Therefore, wearing masks and social distancing in 391 public places could effectively reduce the transmission of respiratory viruses, 392 393 but did not reduce the infection rate of *M. pneumoniae*. Compared with before the COVID-19 pandemic, fewer children with bilateral multilobar infiltrates and 394 pleural effusion were detected by CT scans, and mild inflammatory changes in 395 the mucosa and decreased lumen morphological changes were detected by 396 397 FB. Therefore, it is reasonable to deduce that the NPIs during the COVID-19 pandemic significantly alleviated lung inflammation compared with before the 398 399 pandemic.

400 Several limitations should be taken into consideration in this present study.

First, our study was limited to children requiring BALF and did not include 401 children receiving medical therapy alone or in need of intensive care, and 402 therefore does not fully represent the distribution of characteristics of all CAP 403 pathogens. Second, although testing for common respiratory viruses and 404 atypical bacteria, bacterial detection was restricted to the panel of organisms 405 covered by the SureX 13 respiratory pathogen multiplex kit. This may have 406 resulted in underestimation of the overall detection rate for pathogens. Third, 407 due to the implementation of NPIs, our sample collection time was interrupted 408 409 and were not able to identify the season-dependent changes in the occurrence of CAP caused by each etiology. 410

Despite these limitations, our study suggest that *M. pneumoniae* infection 411 412 might be the greatest pediatric disease burden leading to CAP in northern China. Wearing masks and social distancing in public places can effectively 413 reduce the transmission of respiratory viruses, but cannot reduce the infection 414 rate of *M. pneumoniae*. In addition, the NPIs during the COVID-19 pandemic 415 significantly reduced lung inflammation compared with before the pandemic. 416 Our identifying changes in the pathogen spectrum and clinical characteristics 417 might improve clinical management practices and emphasize the protective 418 419 value of wearing masks and social distancing in children with Community-acquired pneumonia children. in 420

421 Acknowledgments The authors would like to thank the clinical staff,

- 422 specifically the medical doctors and nurses, for their help with collecting clinical
- 423 specimens, and all of the children and their parents for their participation and
- 424 cooperation.

425 **References**

426	1. Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al.
427	Global, regional, and national causes of under-5 mortality in 2000-19: An
428	updated systematic analysis with implications for the Sustainable
429	Development Goals. Lancet Child Adolesc Health. 2022;6:106-15.
430	2. Darby JB, Singh A, Quinonez R. Management of complicated pneumonia
431	in childhood: A review of recent literature. Rev Recent Clin Trials.
432	2017;12:253-9.
433	3. Gao LW, Yin J, Hu YH, Liu XY, Feng XL, He JX, et al. The epidemiology of
434	paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to
435	2016. Epidemiol Infect. 2019;147:e192.
436	4. Lee E, Kim CH, Lee YJ, Kim HB, Kim BS, Kim HY, et al. Annual and
437	seasonal patterns in etiologies of pediatric community-acquired
438	pneumonia due to respiratory viruses and Mycoplasma pneumoniae
439	requiring hospitalization in South Korea. Bmc Infect Dis. 2020;20:132.
440	5. Liu P, Xu M, Cao L, Su L, Lu L, Dong N, et al. Impact of COVID-19
441	pandemic on the prevalence of respiratory viruses in children with lower
442	respiratory tract infections in China. Virol J. 2021;18:159.
443	6. Vittucci AC, Piccioni L, Coltella L, Ciarlitto C, Antilici L, Bozzola E, et al.
444	The disappearance of respiratory viruses in children during the COVID-19
445	pandemic. Int J Environ Res Public Health. 2021;18:9550.
446	7. Li L, Wang H, Liu A, Wang R, Zhi T, Zheng Y, et al. Comparison of 11

447	respiratory pathogens among hospitalized children before and during the
448	COVID-19 epidemic in Shenzhen, China. Virol J. 2021;18:202.
449	8. Takashita E, Kawakami C, Momoki T, Saikusa M, Shimizu K, Ozawa H, et
450	al. Increased risk of rhinovirus infection in children during the coronavirus
451	disease-19 pandemic. Influenza Other Respir Viruses. 2021;15:488-94.
452	9. Agca H, Akalin H, Saglik I, Hacimustafaoglu M, Celebi S, Ener B. Changing
453	epidemiology of influenza and other respiratory viruses in the first year of
454	COVID-19 pandemic. J Infect Public Health. 2021;14:1186-90.
455	10. Wan WY, Thoon KC, Loo LH, Chan KS, Oon L, Ramasamy A, et al. Trends
456	in respiratory virus infections during the COVID-19 pandemic in singapore,
457	2020. JAMA Netw Open. 2021;4:e2115973.
458	11. Kuitunen I, Artama M, Mäkelä L, Backman K, Heiskanen-Kosma T, Renko
459	M. Effect of social distancing due to the COVID-19 pandemic on the
460	incidence of viral respiratory tract infections in children in finland during
461	early 2020. Pediatr Infect Dis J. 2020;39:e423-7.
462	12. Collaborators GLRI. Estimates of the global, regional, and national
463	morbidity, mortality, and aetiologies of lower respiratory infections in 195
464	countries, 1990-2016: A systematic analysis for the Global Burden of
465	Disease Study 2016. Lancet Infect Dis. 2018;18:1191-210.
466	13. Yun KW, Wallihan R, Juergensen A, Mejias A, Ramilo O.
467	Community-Acquired pneumonia in children: Myths and facts. Am J
468	Perinatol. 2019;36:S54-7.

469	14. Radhakrishnan D, Yamashita C, Gillio-Meina C, Fraser DD. Translational
470	research in pediatrics III: Bronchoalveolar lavage. Pediatrics.
471	2014;134:135-54.
472	15. Wang L, Zhao M, Shi Z, Feng Z, Guo W, Yang S, et al. A GeXP-Based
473	assay for simultaneous detection of multiple viruses in hospitalized
474	children with community acquired pneumonia. Plos One.
475	2016;11:e162411.
476	16. Midulla F, de Blic J, Barbato A, Bush A, Eber E, Kotecha S, et al. Flexible
477	endoscopy of paediatric airways. Eur Respir J. 2003;22:698-708.
478	17. Experts Group of Pediatric Respiratory Endoscopy, Talent Exchange
479	Serice Center of National Health Commission Endoscopy Committee,
480	Pediatric Section of Chinese Medical Doctor Association, Pediatric
481	Respiratory Endoscopy Committee, Endoscopists Section of Chinese
482	Medical Doctor Association, Pediaric Interventional Respirology Group,
483	Maternal and Pediatric Minimally Inasive Section of Chinese Maternal and
484	Child Health Association Bronchoscopy Collaboration Subgroup of
485	Respirology Group, Pediatric Section of Chinese Medical Associatio.
486	Guideline of pediatric flexible bronchoscopy in China (2018 version).
487	Zhong Hua Shi Yong Er Ke Lin Chuang Za Zhi. 2018;13:983-989.
488	18. Chen D, Huang Y, Jiao A, Jin R, Liu X, Meng C, et al. Expert consensus on
489	respiratory endoscopic interventional diagnosis and treatment of refractory
490	pneumonia in Chinese children. Zhong Hua Shi Yong Er Ke Za Zhi.

491 2019;34	1:449-57.
-------------	-----------

492	19. Andronikou S, Goussard P, Sorantin E. Computed tomography in children
493	with community-acquired pneumonia. Pediatr Radiol. 2017;47:1431-40.
494	20. Rhedin S, Lindstrand A, Hjelmgren A, Ryd-Rinder M, Ohrmalm L,
495	Tolfvenstam T, et al. Respiratory viruses associated with
496	community-acquired pneumonia in children: Matched case-control study.
497	Thorax. 2015;70:847-53.
498	21. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al.
499	Community-acquired pneumonia requiring hospitalization among U.S.
500	Children. N Engl J Med. 2015;372:835-45.
501	22. Zhang C, Zhu N, Xie Z, Lu R, He B, Liu C, et al. Viral etiology and clinical
502	profiles of children with severe acute respiratory infections in China. Plos
503	One. 2013;8:e72606.
504	23. Kenmoe S, Tchendjou P, Vernet MA, Moyo-Tetang S, Mossus T,
505	Njankouo-Ripa M, et al. Viral etiology of severe acute respiratory infections
506	in hospitalized children in Cameroon, 2011-2013. Influenza Other Respir
507	Viruses. 2016;10:386-93.
508	24. Guo W, Cui X, Wang Q, Wei Y, Guo Y, Zhang T, et al. Clinical evaluation of
509	metagenomic next-generation sequencing for detecting pathogens in
510	bronchoalveolar lavage fluid collected from children with
511	community-acquired pneumonia. Front Med (Lausanne). 2022;9:952636.
512	25. Spuesens EB, Fraaij PL, Visser EG, Hoogenboezem T, Hop WC, van

513	Adrichem LN, et al. Carriage of Mycoplasma pneumoniae in the upper
514	respiratory tract of symptomatic and asymptomatic children: An
515	observational study. Plos Med. 2013;10:e1001444.
516	26. Li YT, Liang Y, Ling YS, Duan MQ, Pan L, Chen ZG. The spectrum of viral
517	pathogens in children with severe acute lower respiratory tract infection:
518	A 3-year prospective study in the pediatric intensive care unit. J Med Virol.
519	2019;91:1633-42.
520	27. Kutty PK, Jain S, Taylor TH, Bramley AM, Diaz MH, Ampofo K, et al.
521	Mycoplasma pneumoniae Among Children Hospitalized with
522	Community-acquired Pneumonia. Clin Infect Dis. 2019;68:5-12.
523	28. Huang L, Huang X, Jiang W, Zhang R, Yan Y, Huang L. Independent
524	predictors for longer radiographic resolution in patients with refractory

525 Mycoplasma pneumoniae pneumonia: A prospective cohort study. Bmj

526 Open. 2018;8:e23719.

527 29. Wang L, Wang W, Sun JM, Ni SW, Ding JL, Zhu YL, et al. Efficacy of
 528 fiberoptic bronchoscopy and bronchoalveolar lavage in childhood-onset,
 529 complicated plastic bronchitis. Pediatr Pulmonol. 2020;55:3088-95.